X4 Pharmaceuticals (XFOR) Earnings Analysis

X4 Pharmaceuticals (XFOR) next reports earnings on 2026-08-06, consensus EPS -0.19 USD. Last quarter (2026-03-17) it beat with EPS -0.22 USD vs -0.36 USD est (+38.9%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -0.81.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does XFOR next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.19 USD
Revenue estimate0.00B

XFOR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-17-0.22 USD-0.36 USD+38.9%Beat
2025-08-08-3.47 USD-4.53 USD+23.4%Beat
2025-05-010.04 USD-4.13 USD+101%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

XFOR valuation and analyst view

Trailing P/E-0.81
Trailing EPS-0.78964 USD
Price / book2.77
Dividend yield0.00%
Market cap0.35B
Analyst consensusBuy (12 buy / 1 hold / 0 sell)
Avg price target11.5 USD

Related research pages

Frequently asked questions

When is X4 Pharmaceuticals (XFOR)'s next earnings date?

X4 Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.19 USD and revenue estimate of 0.00B.

Did XFOR beat earnings last quarter?

In its 2026-03-17 report, XFOR posted EPS of -0.22 USD versus a -0.36 USD estimate — a beat of 38.9%.

What is XFOR's earnings track record?

Over the last 3 reported quarters with consensus data, XFOR beat estimates 3 times (100%).

What is XFOR's current P/E ratio and EPS?

XFOR trades at a trailing P/E of -0.81 on trailing EPS of -0.7896350333671519 USD.

What do analysts rate XFOR?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 11.5 USD.